Cancer Research UK logo.
SearchDonate
  • Search

A trial of APD403 to prevent sickness caused by chemotherapy

Overview

Cancer types:

All cancer types

Status:

Closed

Phase:

Phase 2

Details

This trial is looking at a drug called APD403 to see if it prevents sickness caused by certain chemotherapy drugs.

Doctors often use chemotherapy to treat cancer. Some chemotherapy drugs can make you feel sick or be sick. It can happen on the day you have chemotherapy or during the next few days.

Doctors prescribe anti sickness drugs that you have just before chemotherapy and for the next few days. But even with anti sickness drugs, some people do feel sick after having chemotherapy, so researchers are looking for new drugs to prevent chemotherapy related sickness. In this trial, they are looking at a drug called APD403.

The aim of the trial is to see how good different doses of APD403 are at stopping sickness during the 5 days after chemotherapy.

Recruitment start: 18 October 2013

Recruitment end: 30 January 2015

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Yvonne Summers

Supported by

Acacia Pharma Ltd

NIHR Clinical Research Network: Cancer

Last reviewed: 06 Feb 2015

CRUK internal database number: 11143

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Find a Clinical Trial

Search our clinical trials database for all cancer trials and studies recruiting in the UK.

An icon of two speech bubbles, indicating a conversation.

Cancer Chat forum

Connect with other people affected by cancer and share your experiences.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.